Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Missouri Failed to Collect $12.2M in Medicaid Drug Rebates
The HHS Office of Inspector General (OIG) found that Missouri failed to collect $12.2 million in federal rebates for Medicaid physician-administered and pharmacy drugs between January 1, 2019, and December 31, 2022. The OIG recommends Missouri refund the federal government $9.7 million for physician-administered drugs and $2.5 million for pharmacy drugs.
ACF Contract for Unaccompanied Alien Children Services Noncompliant
The HHS OIG found that the Administration for Children and Families (ACF) awarded a $529 million sole source contract for unaccompanied alien children services in a noncompliant manner. The contract was double the cost estimate and lacked required pre-award documentation.
HHS OIG: West Virginia Failed to Collect $6.1M in Medicaid Drug Rebates
The HHS Office of Inspector General found that West Virginia failed to collect an estimated $6.1 million in federal rebates for physician-administered drugs dispensed to Medicaid managed-care enrollees. The audit identified failures in internal controls that prevented the state from invoicing manufacturers for these rebates.
MHRA Restricts Chikungunya Vaccine IXCHIQ Use
The MHRA has introduced additional restrictions on the use of the Chikungunya vaccine IXCHIQ. The vaccine is now restricted to adults aged 18-59 without specific pre-existing health conditions, following reports of serious adverse reactions, including fatalities. Healthcare professionals must conduct a benefit-risk assessment before administration.
Pharmacy Commission Meeting Minutes and Actions
The Connecticut Commission of Pharmacy met on October 30, 2024, approving a new pharmacy application with modifications, a pharmacy remodel, and issuing fines totaling $3,000 to Walgreens for violations related to pharmacy closures and compounding standards. The commission also approved reciprocity and new applications.
Pharmacy Commission Meeting Agenda - October 30, 2024
The Connecticut Pharmacy Commission meeting agenda for October 30, 2024, outlines discussions on new pharmacy applications, remodels, pharmacy manager appointments, and reciprocity interviews. The agenda also includes requests for new non-resident pharmacy applications and updates on previously approved or denied applications.
Pharmacy Commission Meeting Minutes - Approvals and Enforcement
The Connecticut Commission of Pharmacy approved new pharmacy premises and several pharmacy remodels during its November 20, 2024 meeting. The Commission also initiated an enforcement action against Walgreens #02410 for alleged violations related to pharmacy manager changes and operating without a manager.
Pharmacy Commission Meeting Agenda
The Connecticut Pharmacy Commission met on November 20, 2024, to review 20 new pharmacy applications, including new and non-resident pharmacies, and address two legal cases. The agenda also included discussions on pharmacy remodels and reciprocity interviews.
Connecticut Commission of Pharmacy Meeting Schedule
The Connecticut Commission of Pharmacy has published its upcoming meeting dates and locations for 2024-2026. These notices provide details on regular meeting times, locations, and links to agendas and minutes for public review.
Virginia Board of Pharmacy Staffing Concerns and Statewide Protocols Update
The Virginia Board of Pharmacy has updated its guidance on reporting pharmacy staffing concerns and has amended several statewide protocols for pharmacists. Pharmacy permit holders must review and act on staffing reports, and pharmacists can report issues directly to the board without fear of retaliation. The revised protocols cover vaccinations, tuberculosis testing, hormonal contraceptives, naloxone, influenza, and strep throat.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
720 changes in last 7 days
Latest high priority updates
141 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.